SMALL INTERFERING RNA THERAPEUTICS FOR DIABETES COMPLICATIONS: MECHANISMS, DELIVERY BARRIERS AND CLINICAL PROSPECTS

Diabetes complications remain major causes of visual loss, kidney failure, pain, and disability despite improvements in risk-factor management. Small interfering RNA (siRNA) recruits the RNA-induced silencing complex to degrade a selected messenger RNA, offering sequence-directed suppression of disease-associated genes. This review assesses evidence for siRNA in diabetic retinopathy, kidney disease, and neuropathy, alongside delivery, safety, and clinical translation. Evidence remains uneven and largely preclinical. The strongest human evidence is PF-04523655, an intravitreal siRNA against RTP801/REDD1 tested in a phase 2 diabetic macular edema trial. The highest dose showed a numerical visual-acuity advantage over laser, but the study stopped early under prespecified futility and discontinuation criteria and did not establish efficacy. Kidney candidates, including TGF-β1, Cyp4a14, and podocyte-directed HDAC4, have shown molecular or histological effects in cells or diabetic animals. Neuropathy studies targeting PTEN, IRE1α, PARP1, and long noncoding RNAs report changes in nerve regeneration, electrophysiology, pain behavior, or autonomic measures in rodents. These results do not demonstrate clinical benefit. Eight siRNA medicines had US FDA approval by November 2025, but none treats a diabetic complication. The main barrier is productive, cell-selective delivery beyond the liver. Stability, cellular uptake, endosomal escape, immune activation, off-target silencing, long-term safety, and patient-relevant trial outcomes require further study. siRNA is a promising research platform, not an established treatment for diabetic retinopathy, nephropathy, or neuropathy.

Authors

Publication Details

Journal
Zenodo (CERN European Organization for Nuclear Research)
Published
2026-11-15
DOI
https://doi.org/10.5281/zenodo.24200239
Primary Topic
RNA Interference and Gene Delivery
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

SMALL INTERFERING RNA THERAPEUTICS FOR DIABETES COMPLICATIONS: MECHANISMS, DELIVERY BARRIERS AND CLINICAL PROSPECTS

Preethi V1*, Lathikasaran B2, Boomika R3, Dhanesh Kumar M R4, Dr. Sathish A5
Zenodo (CERN European Organization for Nuclear Research)
RNA Interference and Gene Delivery
article

SMALL INTERFERING RNA THERAPEUTICS FOR DIABETES COMPLICATIONS: MECHANISMS, DELIVERY BARRIERS AND CLINICAL PROSPECTS

Preethi V1*, Lathikasaran B2, Boomika R3, Dhanesh Kumar M R4, Dr. Sathish A5
article en

Abstract

Diabetes complications remain major causes of visual loss, kidney failure, pain, and disability despite improvements in risk-factor management. Small interfering RNA (siRNA) recruits the RNA-induced silencing complex to degrade a selected messenger RNA, offering sequence-directed suppression of disease-associated genes. This review assesses evidence for siRNA in diabetic retinopathy, kidney disease, and neuropathy, alongside delivery, safety, and clinical translation. Evidence remains uneven and largely preclinical. The strongest human evidence is PF-04523655, an intravitreal siRNA against RTP801/REDD1 tested in a phase 2 diabetic macular edema trial. The highest dose showed a numerical visual-acuity advantage over laser, but the study stopped early under prespecified futility and discontinuation criteria and did not establish efficacy. Kidney candidates, including TGF-β1, Cyp4a14, and podocyte-directed HDAC4, have shown molecular or histological effects in cells or diabetic animals. Neuropathy studies targeting PTEN, IRE1α, PARP1, and long noncoding RNAs report changes in nerve regeneration, electrophysiology, pain behavior, or autonomic measures in rodents. These results do not demonstrate clinical benefit. Eight siRNA medicines had US FDA approval by November 2025, but none treats a diabetic complication. The main barrier is productive, cell-selective delivery beyond the liver. Stability, cellular uptake, endosomal escape, immune activation, off-target silencing, long-term safety, and patient-relevant trial outcomes require further study. siRNA is a promising research platform, not an established treatment for diabetic retinopathy, nephropathy, or neuropathy.

Zenodo (CERN European Organization for Nuclear Research)
Good health and well-being
RNA Interference and Gene Delivery
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon